Raymond James downgraded shares of STERIS’ (TSE:STE – Free Report) from a moderate buy rating to a hold rating in a research report report published on Wednesday morning,Zacks.com reports. Raymond James also issued estimates for STERIS’’s FY2025 earnings at $0.54 EPS and FY2027 earnings at $0.48 EPS.
Several other brokerages also recently commented on STE. Atb Cap Markets raised shares of STERIS’ to a “strong-buy” rating in a research report on Sunday, December 22nd. Cormark upgraded shares of STERIS’ to a “moderate buy” rating in a research note on Monday, January 6th.
Get Our Latest Stock Analysis on STE
STERIS’ Price Performance
About STERIS’
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Featured Articles
- Five stocks we like better than STERIS’
- Learn Technical Analysis Skills to Master the Stock Market
- JPMorgan is a Buy, if You Can Handle The Volatility
- Transportation Stocks Investing
- United States Steel’s Crash: An Unmissable Buying Opportunity
- What Are Dividend Achievers? An Introduction
- Rocket Lab Stock: Weathering the Storm, Time for a Comeback?
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
